| For: | Bonnet D, Guivarch M, Bérard E, Combis JM, Remy AJ, Glibert A, Payen JL, Metivier S, Barange K, Desmorat H, Palacin A, Nicot F, Abravanel F, Alric L. Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients. World J Hepatol 2014; 6(9): 660-669 [PMID: 25276282 DOI: 10.4254/wjh.v6.i9.660] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v6/i9/660.htm |
| Number | Citing Articles |
| 1 |
Laurent Alric, Caroline Besson, Nathanael Lapidus, Juliette Jeannel, Jean-Marie Michot, Patrice Cacoub, Danielle Canioni, Stanislas Pol, Frédéric Davi, Pascaline Rabiega, Loic Ysebaert, Delphine Bonnet, Olivier Hermine, Ming-Lung Yu. Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study. PLOS ONE 2016; 11(10) doi: 10.1371/journal.pone.0162965
|
| 2 |
D. Salmon, F. Bani-Sadr, C. Gilbert, E. Rosenthal, M.A. Valantin, A. Simon, D. Neau, P. Morlat, M.A. Loko, L. Wittkop, F. Dabis. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. Journal of Clinical Virology 2015; 73 doi: 10.1016/j.jcv.2015.10.010
|
| 3 |
João Paulo Vilela Rodrigues, Maurílio de Souza Cazarim, Silvana Gama Florencio Chachá, Ana de Lourdes Candolo Martinelli, Leonardo Régis Leira Pereira. Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C. Cadernos de Saúde Pública 2020; 36(2) doi: 10.1590/0102-311x00036619
|
| 4 |
Javier Salmerón, Carmen Vinaixa, Rubén Berenguer, Juan Manuel Pascasio, Juan José Sánchez Ruano, Miguel Ángel Serra, Ana Gila, Moisés Diago, Manuel Romero-Gómez, José María Navarro, Milagros Testillano, Conrado Fernández, Dolores Espinosa, Isabel Carmona, José Antonio Pons, Francisco Jorquera, Francisco Javier Rodriguez, Ramón Pérez, José Luis Montero, Rafael Granados, Miguel Fernández, Ana Belén Martín, Paloma Muñoz de Rueda, Rosa Quiles, Alhambra Spanish Study Group. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. World Journal of Gastroenterology 2015; 21(30): 9163-9174 doi: 10.3748/wjg.v21.i30.9163
|
| 5 |
Alessandra Mangia, Victor De Ledinghen, François Bailly, Javier Brahm, Jazeps Keiss, Jonas Valantinas, Nele Rasmann, Diethelm Messinger, Fernando Tatsch, Georgios Bakalos, Graham R. Foster. IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. SpringerPlus 2016; 5(1) doi: 10.1186/s40064-016-3663-6
|
| 6 |
Timothy A. Bach, Kathy Zaiken. Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1–4 in an ambulatory care setting. American Journal of Health-System Pharmacy 2017; 74(5_Supplement_1) doi: 10.2146/ajhp160567
|
| 7 |
Vanessa Costilla, Neha Mathur, Julio A. Gutierrez. Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment. Clinics in Liver Disease 2015; 19(4) doi: 10.1016/j.cld.2015.06.005
|
| 8 |
J. Boursier, A. Ducancelle, J. Vergniol, P. Veillon, V. Moal, C. Dufour, J.‐P. Bronowicki, D. Larrey, C. Hézode, F. Zoulim, H. Fontaine, V. Canva, T. Poynard, S. Allam, V. De Lédinghen. The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients. Journal of Viral Hepatitis 2015; 22(12) doi: 10.1111/jvh.12433
|
| 9 |
Emma Gray, Suzanne Norris, Susanne Schmitz, Aisling O'Leary. Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?. Journal of Comparative Effectiveness Research 2017; 6(1) doi: 10.2217/cer-2016-0042
|
| 10 |
Antonia Lepida, Massimo Colombo, Inmaculada Fernandez, Djamal Abdurakhmanov, Paulo Abrao Ferreira, Simone I. Strasser, Petr Urbanek, Alessandra Mangia, José L. Calleja, Wafae Iraqi, Ralph DeMasi, Isabelle Lonjon-Domanec, Christophe Moreno, Heiner Wedemeyer, Vincent Wong. Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. PLOS ONE 2015; 10(9) doi: 10.1371/journal.pone.0138503
|
| 11 |
CLEO Study Group, Antonio Ascione, Luigi Elio Adinolfi, Pietro Amoroso, Angelo Andriulli, Orlando Armignacco, Tiziana Ascione, Sergio Babudieri, Giorgio Barbarini, Michele Brogna, Francesco Cesario, Vincenzo Citro, Ernesto Claar, Raffaele Cozzolongo, Giuseppe D’Adamo, Emilio D’Amico, Pellegrino Dattolo, Massimo De Luca, Vincenzo De Maria, Massimo De Siena, Giuseppe De Vita, Antonio Di Giacomo, Rosanna De Marco, Giorgio De Stefano, Alfredo Vallone, Paolo Tundo, Pierluigi Tarquini, Annarita Sullo, Filomena Simeone, Gaetano Scifo, Antonio Sciambra, Antonio Schiano, Vincenzo Sangiovanni, Rodolfo Sacco, Grazia Russo, Maurizio Russello, Angelo Rossini, Mario Romano, Luca Rinaldi, Francesco Resta, Grazia Pietromatera, Paola Pierri, Antonio Picardi, Guido Piai, Alessandro Perrella, Adriano Maria Pellicelli, Lorenzo Nosotti, Vincenzo Narciso, Roberto Monarca, Vincenzo Messina, Ettore Mazzoni, Aldo Marrone, Ileana Luppino, Gennaro Lettieri, Pietro Leo, Alfonso Liberti, Antonio Izzi, Vincenzo Iovinella, Angelo Iodice, Michele Imparato, Angelo Iacobellis, Roberto Gulminetti, Barbara Guerrera, Tiziana Gravina, Giancarlo Giolitto, Francesca Giancotti, Caterina Furlan, Giuseppe Foti, Luca Fontanella, Basilio Fimiani, Laura Felicioni, Nunzia Farella, Raffaele Di Sarno, Sebastiano Di Salvo, Giulio De Stefano. Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. World Journal of Hepatology 2016; 8(22): 949-956 doi: 10.4254/wjh.v8.i22.949
|
| 12 |
Perica Davitkov, Apoorva Krishna Chandar, Amy Hirsch, Anita Compan, Marina G. Silveira, Donald D. Anthony, Suzanne Smith, Clare Gideon, Robert A. Bonomo, Yngve Falck-Ytter, Do Young Kim. Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C. PLOS ONE 2016; 11(10) doi: 10.1371/journal.pone.0163945
|
| 13 |
Silvana Gama Florencio Chachá, João Paulo Vilela Rodrigues, Roberta Chaves Araújo, Leonardo Régis Leira Pereira, Márcia Guimarães Villanova, Fernanda Fernandes Souza, Rodrigo de Carvalho Santana, Ana de Lourdes Candolo Martinelli. First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients. Revista da Sociedade Brasileira de Medicina Tropical 2018; 51(2) doi: 10.1590/0037-8682-0153-2017
|